Celgene

Quick facts

Marketed products

• Istodax · Oncology
• low-dose dexamethasone · Immunology
  Low-dose dexamethasone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.
• Pneumococcal polysaccharide vaccine · Immunology / Infectious Disease
  Pneumococcal polysaccharide vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae, providing protection against pneumococcal infection.

Phase 3 pipeline

• Abraxane (Induction) · Oncology
  Abraxane is a nanoparticle albumin-bound paclitaxel that stabilizes microtubules to inhibit cell division and induce apoptosis in cancer cells.
• Abraxane (Maintenance) · Oncology
  Abraxane is a nanoparticle albumin-bound paclitaxel that stabilizes microtubules to inhibit cell division and induce apoptosis in cancer cells.
• AG-221
• bb2121 · Oncology
  bb2121 is a chimeric antigen receptor (CAR) T-cell therapy that redirects a patient's own T cells to recognize and kill multiple myeloma cells expressing BCMA.
• BMS-986365 · Oncology
  BMS-986365 is a selective inhibitor of menin that disrupts the interaction between menin and mixed-lineage leukemia (MLL) proteins, restoring normal gene expression in leukemic cells.
• Carboplatin (Induction) · Oncology
  Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing cell death.
• CC-5013 plus dexamethasone · Oncology
  CC-5013 (lenalidomide) is an immunomodulatory agent that enhances T-cell proliferation and cytokine production while dexamethasone provides corticosteroid-mediated anti-inflammatory and anti-proliferative effects.
• CC-93538 · Oncology
  CC-93538 is a cereblon E3 ligase modulator (CELMoD) that degrades Ikaros and Ikzf3 proteins to enhance T-cell proliferation and anti-tumor immunity.
• Conventional Care Regimen
  Conventional Care Regimen is a standard-of-care treatment protocol rather than a single drug, typically consisting of established therapeutic agents used as a comparator arm in clinical trials.
• Lenalidomide and low-dose dexamethasone · Oncology
  Lenalidomide enhances immune cell activity and has anti-angiogenic and anti-proliferative effects, while dexamethasone provides anti-inflammatory and immunosuppressive activity to reduce myeloma cell growth.
• Low-dose cytarabine (LDAC) · Oncology
  Low-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and blocking cell division, primarily affecting rapidly dividing hematopoietic cells.
• Placebo to interferon beta-1a · Immunology
  Interferon beta-1a activates interferon signaling pathways to modulate immune responses and reduce inflammatory activity.
• Placebo to ozanimod · Immunology
  Ozanimod is a selective sphingosine-1-phosphate (S1P) receptor modulator that reduces lymphocyte egress from lymphoid tissues, decreasing circulating lymphocytes and inflammatory cell infiltration into affected tissues.
• Predinsone/Prednisolone · Immunology, Rheumatology, Oncology (supportive care), Endocrinology
  Prednisone/prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
• RPC1063 · Oncology
  RPC1063 is a sphingosine 1-phosphate receptor modulator.

Phase 2 pipeline

• ACE-011 · Hematology/Oncology
  ACE-011 is an activin receptor type IIA ligand trap that inhibits activin signaling to promote erythropoiesis and increase hemoglobin levels.
• BMS-986368 · Oncology
  BMS-986368 is an anti-PD-1 monoclonal antibody.
• CC-122 · Oncology
  CC-122 is a selective inhibitor of the immunoproteasome.
• CC-2001 · Oncology
  CC-2001 is a histone deacetylase inhibitor.
• CC-220 · Immunology
  CC-220 is a small molecule that modulates the activity of cereblon, an E3 ubiquitin ligase, leading to the degradation of specific proteins involved in inflammation and immune responses.
• CDC-501 · Oncology
  CDC-501 is a cereblon E3 ligase modulator that degrades specific proteins involved in immune regulation and cell proliferation.
• Duravalumab · Other
• IMNOVID
• Investigators choice single agent
• JCAR017 · Oncology
  JCAR017 is a CD19-directed CAR T-cell therapy designed to target and eliminate CD19-positive B cells.
• Lenalomide · Other
• nab-paclitaxel IV
• Nonconforming idecabtagene vicleucel
• Oral Fedratinib · Oncology
  JAK2 inhibitor
• Paclitaxel Nanoparticle Albumin Bound
• RPC4046
• Safety and efficacy assessments

Phase 1 pipeline

• [14C] BMS-986365
• [14C]-BMS-986368
• [14C]CC-90001
• [14C]-CC-92480
• [18F]T-401
• ABI-008
• Arm 1 probes
• AVL-292
• CC-223, erlotinib
• CC-223, oral azacitidine
• CC-92480
• CC-95775
• CC1083610
• CC1083611
• CYP substrates
• NPI-0052
• NPI-0052 on Days 1, 4, 8, 11 every 21 days
• NPI-0052 on Days 1, 8, 15 every 28 days
• Rasigiline · Other
• Thalidomide Celgene™

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Celgene portfolio CI brief
• Celgene pipeline updates RSS